Maria T Millan
Affiliation: Stanford University
- One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experienceMaria T Millan
Stanford University School of Medicine, Palo Alto, CA 94304, USA
Transplantation 76:1458-63. 2003..Although others have reported on overall results of transplantation for PH1 covering a wide age spectrum, none has specifically addressed the high-risk infantile form of the disease...
- Tolerance and chimerism after renal and hematopoietic-cell transplantationJohn D Scandling
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
N Engl J Med 358:362-8. 2008..Adverse events requiring hospitalization were limited to a 2-day episode of fever with neutropenia. The patient has had neither rejection episodes nor clinical manifestations of graft-versus-host disease...
- Liver allografts are toleragenic in rats conditioned with posttransplant total lymphoid irradiationKazuhito Nagasaki
Department of Surgery, Division of Transplantation, Stanford University School of Medicine, Stanford, CA, USA
Transplantation 84:619-28. 2007..Posttransplant total lymphoid irradiation (TLI) treatment has been applied to tolerance induction protocols in heart and kidney transplantation models...
- Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantationMelissa Hurwitz
Department of Pediatrics, Stanford University, Palo Alto, CA 94304, USA
Pediatr Transplant 8:267-72. 2004..Episodes of rejection that occur after stopping IMS can be successfully treated with standard therapy without graft loss to acute rejection...
- Dual-kidney transplantation with organs from expanded criteria donors: a long-term follow-upJane C Tan
Kidney and Pancreas Transplant Program, Stanford University Medical Center, 750 Welch Road, Palo Alto, CA 94304 1509, USA
Transplantation 78:692-6. 2004..We now have 8-year follow-up in the first recipients. Older individuals were offered this option preferentially, because we reasoned that they would stand to benefit most from the shorter waiting period...
- Approaches to transplantation tolerance in humansSamuel Strober
Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5166, USA
Transplantation 77:932-6. 2004..Preclinical and clinical studies of the use of total lymphoid irradiation for the induction of chimeric and nonchimeric tolerance are summarized here...
- Cell-based therapies for metabolic liver diseaseGregory M Enns
Division of Medical Genetics, Department of Pediatrics, Lucile Packard Children s Hospital, Stanford University, Stanford, CA, 94305 5208, USA
Mol Genet Metab 95:3-10. 2008..Cell-based therapies, including those based on stem cells or more differentiated progenitor cells, may represent the future of cell transplantation for treatment of metabolic liver disease...
- Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cellsEric Chiao
Stanford University, Palo Alto, California, USA
Stem Cells 26:2032-41. 2008..Disclosure of potential conflicts of interest is found at the end of this article...
- Epstein-Barr virus latent membrane protein 1 activates nuclear factor-kappa B in human endothelial cells and inhibits apoptosisAnming Xiong
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94304, USA
Transplantation 78:41-9. 2004..The in vivo effect of latent EBV in the vascular endothelium of the transplanted allograft and its resultant impact on transplant vasculopathy are the subject of further investigations in our laboratory...
- Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantationMaria T Millan
Department of Surgery, Division of Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA
Transplantation 73:1386-91. 2002..Conditioning of the host with posttransplant TLI and ATG was nonmyeloablative and was not associated with severe infections. Recipients continue to be studied for the development of immune tolerance...